FEB 27, 2019 06:45 PM PST

Are They Really Killer-T Cells?

Scientists at the University of Virginia School of Medicine have discovered a defect in immune cells known as "killer T cells" that explains their inability to destroy cancer tumors. The researchers believe that repairing this defect could make the cells much better cancer killers. Further, they predict their discovery could be used within three to five years to help identify patients who will best respond to cancer therapies.

The finding could be a significant boost to the burgeoning field of immunotherapy, which aims to harness the body's immune defenses to defeat cancer. The discovery could also let doctors better predict and assess how well a patient responds to treatment.

"For a long time, the presence of immune cells in cancer has been associated with a better outcome in patients, but it's not been clear why the immune cells haven't been able to control the cancer. What is the cancer doing?" said researcher Timothy Bullock, Ph.D., of the UVA Cancer Center. "This [finding] gives us plenty of opportunities to come in with interventions to invigorate these T cells and level the playing field substantially, so they're much more competitive."

Building Better Cancer Killers

Despite their fearsome moniker, "killer" T cells often become inactive in solid tumors. UVA's new research sheds light on why. Bullock and his team determined that these sluggish soldiers suffer from a dysfunctional enzyme, enolase 1. Without it, they cannot use a vital nutrient, glucose.

"There is a functional defect in this enzyme that is preventing the cells from breaking down glucose and using it in such a way that they can proliferate and become functional," explained researcher Lelisa F. Gemta. "They don't process it well, and that's what we've been digging into: to find out why do these cells take up glucose but fail to break it down."

By ramping up the effectiveness of the enzyme, the researchers believe they can make the killer T cells much better at killing cancer. The sluggish soldiers would become much more formidable fighters.

The researchers also believe that doctors will be able to examine the enzyme to predict how well a patient will respond to treatment. "I think that there is an opportunity to actually use this enzyme as a read-out for the quality of the T cells that are in the tumor, so that when a physician comes in with a clinical trial, we can theoretically analyze how the T cells metabolically compare within the tumor," said Bullock, of UVA's Department of Pathology. "It's almost a biomarker of immune function and fitness within the tumors."

The research is part of UVA's aggressive efforts to advance the field of immunotherapy. For example, it is conducting a leading-edge clinical trial of experimental immunotherapy for pediatric acute lymphoblastic leukemia that has resisted other forms of treatment. The approach, known as chimeric antigen receptor T-cell therapy, takes a child's immune cells and genetically modifies them to make them better at killing cancer.

By confronting the defect, they have discovered and making these T cells fitter, Bullock hopes that his discovery will complement such emerging treatments and make them more effective. The finding, he notes, also might be put to use one day to dampen excessive immune responses, such as are seen in autoimmune disorders.

Sources: Science Daily, Science, YouTube

About the Author
You May Also Like
NOV 14, 2018
Immunology
NOV 14, 2018
Rapid Tumor Targeting
Researchers at the University of California Irvine have developed a technology that will rapidly identify and target T cell receptors for tumor specific antigens...
NOV 28, 2018
Immunology
NOV 28, 2018
Regulators to the Rescue
Scientists at Scripps Research Institute describe the nature of an immune regulator protein...
DEC 04, 2018
Immunology
DEC 04, 2018
Why is Skin Cancer so Elusive?
A pathway involved in skin cancer reveals a potential immunotherapy target...
JAN 23, 2019
Immunology
JAN 23, 2019
Can Old Cells Have Positive Impacts on MS Patients?
A new study shows that there is a very limited regeneration of cells in the brain of patients diagnosed with multiple sclerosis (MS)....
JAN 23, 2019
Immunology
JAN 23, 2019
The Effects of Space: Immunology
A team of researchers studied the effects of spaceflights of six months or more on natural killer cells, or NK cells, a type of white blood cell that kills cancerous cells in the body....
FEB 13, 2019
Immunology
FEB 13, 2019
If I Only Had a Brain
Research scientists have demonstrated that immune cells make brain chemicals to fight off infections....
Loading Comments...